Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to move to phase III trials of new melanoma treatments

Roche to move to phase III trials of new melanoma treatments

8th November 2016

Roche has announced plans to initiate two phase III pivotal trials for innovative melanoma therapies that have shown promise in earlier studies.

The company has presented data at the International Congress of the Society for Melanoma Research showing that its new method of combining targeted and immunotherapy treatment approaches has demonstrated strong results.

A phase Ib study of previously untreated BRAF V600 mutation-positive metastatic melanoma patients indicated that a combination of Tecentriq plus Cotellic and Zelboraf was well-tolerated, showing efficacy in the majority of patients.

In a separate phase Ib trial, Tecentriq plus Cotellic was also shown to offer promising efficacy in patients with BRAF-wild-type and BRAF-mutant metastatic melanoma.

The company also announced updated data from the phase III coBRIM study, confirming long-term overall survival benefits associated with the use of Cotellic plus Zelboraf, compared to Zelboraf alone, for BRAF V600 mutation-positive forms of the cancer.

Dr Sandra Horning, Roche's chief medical officer and head of global product development, said: "We are encouraged by these early results, which demonstrate a high proportion of people responded to these investigational combination therapies."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801828034-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.